Vanda Pharmaceuticals Stock In The News
| VNDA Stock | USD 4.98 0.06 1.22% |
Our overall analysis of Vanda Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Vanda Pharmaceuticals. The specific impact of Vanda Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Vanda Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Vanda Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Vanda Pharmaceuticals Backtesting and Vanda Pharmaceuticals Hype Analysis. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
Vanda |
Vanda Pharmaceuticals Today Top News and Investor Outlook
Vanda Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Vanda and other traded companies coverage with news coverage. We help investors stay connected with Vanda headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Vanda Stock performance. Please note that trading solely based on the Vanda Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Vanda Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Vanda earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Vanda Pharmaceuticals that are available to investors today. That information is available publicly through Vanda media outlets and privately through word of mouth or via Vanda internal channels. However, regardless of the origin, that massive amount of Vanda data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vanda Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vanda Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vanda Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vanda Pharmaceuticals alpha.
Vanda Largest EPS Surprises
Earnings surprises can significantly impact Vanda Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-10-28 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2017-05-02 | 2017-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2015-11-03 | 2015-09-30 | -0.2 | -0.22 | -0.02 | 10 | ||
2022-11-02 | 2022-09-30 | 0.09 | 0.06 | -0.03 | 33 | ||
2022-02-23 | 2021-12-31 | 0.09 | 0.12 | 0.03 | 33 | ||
2021-07-28 | 2021-06-30 | 0.14 | 0.17 | 0.03 | 21 |
Vanda Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Vanda Pharmaceuticals Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
13th of March 2025
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provide... at finance.yahoo.com
7th of March 2025
Insider Buying Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals I... at gurufocus.com
5th of March 2025
Acquisition by Polymeropoulos Mihael Hristos of 5000 shares of Vanda Pharmaceuticals at 5.... at MacroaxisInsider
28th of February 2025
Insider Buying Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals I... at gurufocus.com
27th of February 2025
Acquisition by Polymeropoulos Mihael Hristos of 10000 shares of Vanda Pharmaceuticals at 4... at gurufocus.com
26th of February 2025
Acquisition by Polymeropoulos Mihael Hristos of 5000 shares of Vanda Pharmaceuticals at 4.... at thelincolnianonline.com
21st of February 2025
Acquisition by Kevin Moran of 2000 shares of Vanda Pharmaceuticals at 4.3894 subject to Ru... at MacroaxisInsider
14th of February 2025
Vanda Pharmaceuticals Inc Q4 2024 Earnings Call Highlights Revenue Growth Amidst Challenge... at gurufocus.com
30th of January 2025
Disposition of 412 shares by Kevin Moran of Vanda Pharmaceuticals at 6.3 subject to Rule 1... at MacroaxisInsider
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vanda Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vanda Pharmaceuticals' short interest history, or implied volatility extrapolated from Vanda Pharmaceuticals options trading.
Check out Vanda Pharmaceuticals Backtesting and Vanda Pharmaceuticals Hype Analysis. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (0.19) | Revenue Per Share | Quarterly Revenue Growth 0.228 | Return On Assets |
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.